⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19662328 | 1.00 | — | — | |
| SCHEMBL855476 | 1.00 | — | — | |
| SCHEMBL10232278 | 1.00 | — | — | |
| SCHEMBL26085597 | 1.00 | — | — | |
| SCHEMBL28230079 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL20983360 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL20983270 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL2730680 | 0.97 | — | — | |
| SCHEMBL22242701 | 0.88 | — | — | |
| SCHEMBL21974278 | 0.76 | SI (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259849-A1 | Azine-Carboxamides as Anti-Cancer Agents | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | claimed |
| CN-101023063-A | Azine-carboxamides as anti-cancer agents | ASTRAZENECA AB (SE) | 2007-08-22 | — | — | CN | claimed |
| EP-1765790-A1 | AZINE-CARBOXAMIDES AS ANTI-CANCER AGENT | AstraZeneca AB (SE) | 2007-03-28 | — | — | EP | claimed |
| WO-2006003378-A1 | AZINE-CARBOXAMIDES AS ANTI-CANCER AGENT | ASTRAZENECA AB (SE) | 2006-01-12 | — | — | WO | claimed |
| EP-4029868-B1 | MCL-1 INHIBITORS | GILEAD SCIENCES INC (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-3583105-B1 | PYRROLO [1,2-B]PYRIDAZINE DERIVATIVES | GILEAD SCIENCES INC (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-108137542-B | Pyridone dicarboxamides as bromodomain inhibitors | 葛兰素史克知识产权第二有限公司 | 2023-10-27 | — | — | CN | disclosed |
| US-20230312490-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-10-05 | — | — | US | disclosed |
| US-11643400-B2 | MCL-1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-20220340535-A1 | MCL-1 INHIBITORS | GILEAD SCIENCES, INC. | 2022-10-27 | — | — | US | disclosed |
| US-11339166-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | GALAPAGOS NV (BE) | 2022-05-24 | — | — | US | disclosed |
| EP-3717471-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2022-01-05 | — | — | EP | disclosed |
| US-20070259849-A1 | Azine-Carboxamides as Anti-Cancer Agents | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| CN-101023063-A | Azine-carboxamides as anti-cancer agents | ASTRAZENECA AB (SE) | 2007-08-22 | — | — | CN | disclosed |
| EP-1775298-A1 | THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY | Daiichi Asubio Pharma Co., Ltd. (JP) | 2007-04-18 | — | — | EP | disclosed |
| EP-1765790-A1 | AZINE-CARBOXAMIDES AS ANTI-CANCER AGENT | AstraZeneca AB (SE) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006003378-A1 | AZINE-CARBOXAMIDES AS ANTI-CANCER AGENT | ASTRAZENECA AB (SE) | 2006-01-12 | — | — | WO | disclosed |
| WO-1999064048-A9 | INHIBITORS OF HIV REVERSE TRANSCRIPTASE | ADVANCED MEDICINE INC (US) | 2000-07-20 | — | — | WO | disclosed |
| EP-1003541-A1 | INHIBITORS OF HIV REVERSE TRANSCRIPTASE | Advanced Medicine, Inc. (US) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999064048-A1 | INHIBITORS OF HIV REVERSE TRANSCRIPTASE | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |